SIRT1 and cardiomyopathy: Our findings hence support the therapeutic potential of apigenin in the treatment of Dox-induced cardiomyopathy, and highlight the Sirt1/Atf5/UPRmt axis as a promising target for the design and development of drugs against Dox-related cardiotoxicity.